Affordable Access

deepdyve-link
Publisher Website

Therapeutic erythroapheresis: Experience in patients with polycythemia vera and secondary erythrocytosis.

Authors
  • Parra Salinas, Ingrid1
  • Recasens Flores, Valle1
  • Montañés, María Ángeles1
  • García-Erce, José Antonio2
  • 1 Servicio de Hematología y Hemoterapia, Hospital Miguel Servet, Zaragoza, España.
  • 2 Banco de Sangre y Tejidos de Navarra, Pamplona, España; Grupo de Trabajo de la Sociedad Española de Transfusión Sanguínea «Hemoterapia basada en sentido común», España. Electronic address: [email protected]
Type
Published Article
Journal
Medicina Clínica
Publisher
Elsevier
Publication Date
Jan 10, 2020
Volume
154
Issue
1
Pages
16–19
Identifiers
DOI: 10.1016/j.medcli.2018.12.016
PMID: 30795904
Source
Medline
Keywords
Language
Spanish
License
Unknown

Abstract

Therapeutic erythrocytapheresis (TE) is a more efficient strategy compared to phlebotomy to deplete levels of haematocrit in primary and secondary erythrocytosis. To analyse response rate and safety profile of TE in polycythemia vera (PV) and secondary erythrocytosis (SE). Retrospective review of all patients with PV or SE treated with TE, due to phlebotomy failure, or comorbidities that prevented changes of blood volumen. 217 TE sessions (48 PV and 79 SE) corresponding to 20 patients (12 ES and 8 PV). Response were achieved in 87.5% of PV patients and in 50% of SE patients. Adverse effects related to TE performance occurred in 7.08%. Despite our small sample size and the heterogeneous nature of the patients included, we can postulate that TE is a secure strategy that can achieve haematocrit depletion in a shorter time than phlebotomy, specifically in PV patients and in selected cases of SE with expected haemodynamic intolerance to phlebotomies or in patients who fail to respond to phlebotomies. Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

Report this publication

Statistics

Seen <100 times